CHRT stock news
This page provides real-time market news, earnings updates, and company announcements related to Cohort plc (CHRT).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-11 10:59 GMT
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-05 21:12:18
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Finviz2026-03-05 21:12:18
The Zacks Analyst Blog Highlights Datadog's, Dynatrace and Elastic
Finviz2026-03-06 11:36:51
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-06 12:46:17
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
Finviz2026-03-06 13:04:13
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
Finviz2026-03-06 15:25:24
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
Finviz2026-03-06 15:22:07
Opendoor (OPEN) Reports Q4 2025 Results and 300% Increase in Acquisition Velocity
Finviz2026-03-06 19:48:58
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Finviz2026-03-08 22:03:39
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Finviz2026-03-08 22:03:39
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset
Finviz2026-03-09 11:33:52
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Finviz2026-03-09 11:36:44
First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Finviz2026-03-09 12:03:08
OPEN Sets Sights on 6,000 Acquisitions: Is Profitable Growth Achievable for the Platform?
101 finance2026-03-09 17:34:00
enGene's BLA Submission Looms as Binary Catalyst with Strong Preliminary Data and Extended Runway
101 finance2026-03-09 18:01:08
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Finviz2026-03-09 21:45:39
Roblox Shares Slide 1.39 as $700M Surge in Volume Propels Stock to 204th in Market Activity Amid Strategic Push for Older Demographics
101 finance2026-03-09 23:28:04
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
Finviz2026-03-10 11:07:13
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Finviz2026-03-10 11:36:05
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Finviz2026-03-10 12:09:08
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-10 20:03:45
Skye Bioscience’s 2025 Q4 Call: ENHANZE Readiness, Dose Selection, and Delivery Method Claims Clash
101 finance2026-03-10 23:00:59
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
Finviz2026-03-06 13:04:13
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
Finviz2026-03-06 15:25:24
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
Finviz2026-03-06 15:22:07
Opendoor (OPEN) Reports Q4 2025 Results and 300% Increase in Acquisition Velocity
Finviz2026-03-06 19:48:58
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Finviz2026-03-08 22:03:39
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Finviz2026-03-08 22:03:39
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset
Finviz2026-03-09 11:33:52
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Finviz2026-03-09 11:36:44
First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Finviz2026-03-09 12:03:08
OPEN Sets Sights on 6,000 Acquisitions: Is Profitable Growth Achievable for the Platform?
101 finance2026-03-09 17:34:00
enGene's BLA Submission Looms as Binary Catalyst with Strong Preliminary Data and Extended Runway
101 finance2026-03-09 18:01:08
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Finviz2026-03-09 21:45:39
Roblox Shares Slide 1.39 as $700M Surge in Volume Propels Stock to 204th in Market Activity Amid Strategic Push for Older Demographics
101 finance2026-03-09 23:28:04
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
Finviz2026-03-10 11:07:13
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Finviz2026-03-10 11:36:05
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Finviz2026-03-10 12:09:08
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-10 20:03:45
Skye Bioscience’s 2025 Q4 Call: ENHANZE Readiness, Dose Selection, and Delivery Method Claims Clash
101 finance2026-03-10 23:00:59
CHRT stock price change
On the last trading day, CHRT stock closed at 1362.00 GBP, with a price change of 0.29% for the day.
Trade stock perpsCHRT stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more